Evidence map›Paper›PMID 42382224›Full record

ArticleJournal of cardiac failure - intersections2026

Provider Preferences About a Polypill for Heart Failure With Reduced Ejection Fraction: Development of a Multicenter Physician Survey Containing a Discrete Choice Experiment.

Colette Dejong, Justin C Chen, Mansi Agarwal, Noelle LE Tourneau, Adam Hively, Elvin Geng, Matthew S Durstenfeld, Matthew D Hickey, Blake Angell, Dhruv S Kazi and 6 more

Abstract read
In one paragraph

Article in Journal of cardiac failure - intersections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Colette DejongVA Palo Alto Health Care System, Palo Alto, CA, USA.
Justin C ChenCardiovascular Division and Global Health Center, Washington University School of Medicine, St. Louis, MO, USA.
Mansi AgarwalInstitute for Informatics, Data Science and Biostatistics, Washington University School of Medicine, St Louis, MO, United States.
Noelle LE TourneauDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.
Adam HivelyCardiovascular Division and Global Health Center, Washington University School of Medicine, St. Louis, MO, USA.
Elvin GengDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.
Matthew S DurstenfeldDivision of Cardiology, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA.
Matthew D HickeyDivision of HIV, Infectious Disease, and Global Medicine, University of California San Francisco, San Francisco, CA, USA.
Blake AngellThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Dhruv S KaziRichard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Mark D HuffmanCardiovascular Division and Global Health Center, Washington University School of Medicine, St. Louis, MO, USA.
Alexander T SandhuVA Palo Alto Health Care System, Palo Alto, CA, USA.
Paul A HeidenreichVA Palo Alto Health Care System, Palo Alto, CA, USA.
Charles W GossInstitute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.
Priscilla Y HsueDivision of Cardiovascular Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Anubha AgarwalCardiovascular Division and Global Health Center, Washington University School of Medicine, St. Louis, MO, USA.

Funding

Role of Hematopoietic System and Proteomics in HIV-Associated CardiovascularDiseaseK24AI112393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y. · 2014 to 2024
$1.9M
VOCAL COMMUNICATION AND BEHAVIORR01MH062249 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI CHENEY, DOROTHY L · 2000 to 2006
$1.3M
Implementation Strategies to Improve Hypertension Treatment in KenyaK23HL162578 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Matthew Hickey · 2022 to 2026
$944k
The Effect of Value-based Payment on Heart Failure Quality of Care (Value-HF)K23HL151672 · NHLBI · STANFORD UNIVERSITY · PI SANDHU, ALEXANDER · 2020 to 2024
$854k
Heart Failure Polypill in India: A Late-Stage Implementation StrategyR00HL157687 · NHLBI · WASHINGTON UNIVERSITY · PI ANUBHA AGARWAL · 2025 to 2026
$607k
Low Cardiorespiratory Fitness and Chronotropic Incompetence inHIV: Risk Factors, Cardiovascular Implications, and Exercise Training as TreatmentK23HL172699 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Matthew Durstenfeld · 2024 to 2026
$593k
NHLBI NIH HHS K23 HL151672NHLBI NIH HHS K23 HL162578NHLBI NIH HHS K23 HL172699NHLBI NIH HHS R00 HL157687NIAID NIH HHS K24 AI112393NIMH NIH HHS R01 MH062249
6 · The paper itself

Abstract

Background: Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) reduces mortality rates but remains widely underused. A polypill for HFrEF has been proposed as an implementation strategy to improve GDMT delivery, but little is known about physicians' preferences in the design of HFrEF polypills. Discrete choice experiments (DCEs), in which survey respondents choose among hypothetical products, are a powerful tool in health economics research and can lend insight into key tradeoffs in HFrEF polypill design. However, the process of designing DCEs is complex and often poorly reported. Methods: We developed a survey instrument, including a DCE, through a 5-stage mixed-methods process including (1) literature review; (2) physician interviews and surveys; (3) attribute generation; (4) expert review; and (5) pilot testing. We applied a D-efficient design approach using a multinomial logic model to determine the number of choice tasks for the DCE. Results: We designed a DCE with 4 attributes: HFrEF polypill out-of-pocket cost, inclusion of an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, or sacubitril/valsartan, ancillary support for polypill prescribing, and pharmacy availability. The final survey will be distributed to cardiologists in academic and Veterans Administration medical centers across the United States. Conclusions: Through a rigorous multistage design process leveraging mixed methods, we developed a DCE that elicits cardiologists' preferences about HFrEF polypills and key tradeoffs in their design. Results from this DCE study will directly inform future HFrEF polypill cluster-randomized clinical trials.

Indexed as

adherencediscrete choice experimentHeart failure with reduced ejection fraction

Identifiers

PMID42382224
PMCPMC13318422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.